Company intelligence / Profile preview
Histogen Inc.
San Diego, California, United States
- Ownership
- Public · HSTOQ
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
Histogen’s lead product emricasan has shown potential to treat infections by restoring immune competence without generating resistance. The company’s technology has also demonstrated hair growth induction in multiple clinical trials. Other pipeline assets target inflammatory conditions using selective caspase inhibition.
- Therapeutic areas
- ImmunologyDermatologyInfectious Diseases
- Modalities
- Small moleculesBiologics (regenerative medicine products)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $1.3B
- Total revenue
- $257.3M
- Enterprise value
- $998.5M
Beyond the preview
Go deeper on Histogen Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Histogen Inc..